CO7131388A2 - Métodos de quelatos de oligonucleótidos - Google Patents
Métodos de quelatos de oligonucleótidosInfo
- Publication number
- CO7131388A2 CO7131388A2 CO14254326A CO14254326A CO7131388A2 CO 7131388 A2 CO7131388 A2 CO 7131388A2 CO 14254326 A CO14254326 A CO 14254326A CO 14254326 A CO14254326 A CO 14254326A CO 7131388 A2 CO7131388 A2 CO 7131388A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- oligonucleotide chelate
- oligonucleotide
- chelate methods
- hypertriglyceridemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- AIDS & HIV (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Obesity (AREA)
Abstract
Se describen composiciones farmacéuticas y métodos para el tratamiento de infecciones virales, hipercolesterolemia, hipertrigliceridemia, alzheimer, enfermedades causadas por priones y distrofia muscular de Duchenne con quelatos de oligonucleótidos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648694P | 2012-05-18 | 2012-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7131388A2 true CO7131388A2 (es) | 2014-12-01 |
Family
ID=49581827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14254326A CO7131388A2 (es) | 2012-05-18 | 2014-11-19 | Métodos de quelatos de oligonucleótidos |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9616083B2 (es) |
| EP (1) | EP2849760B1 (es) |
| JP (2) | JP6294308B2 (es) |
| KR (1) | KR101975915B1 (es) |
| CN (1) | CN104379152B (es) |
| AR (1) | AR091065A1 (es) |
| AU (1) | AU2013262415B2 (es) |
| BR (1) | BR112014028568B1 (es) |
| CA (1) | CA2873526C (es) |
| CL (1) | CL2014003135A1 (es) |
| CO (1) | CO7131388A2 (es) |
| CR (1) | CR20140522A (es) |
| CU (1) | CU20140132A7 (es) |
| CY (1) | CY1122856T1 (es) |
| DK (1) | DK2849760T3 (es) |
| DO (1) | DOP2014000263A (es) |
| EA (1) | EA034799B1 (es) |
| EC (1) | ECSP14027542A (es) |
| ES (1) | ES2767333T3 (es) |
| HK (1) | HK1206259A1 (es) |
| HR (1) | HRP20200045T1 (es) |
| HU (1) | HUE047456T2 (es) |
| IL (1) | IL235402B (es) |
| IN (1) | IN2014DN08982A (es) |
| LT (1) | LT2849760T (es) |
| MX (1) | MX360626B (es) |
| MY (1) | MY168209A (es) |
| NZ (1) | NZ701931A (es) |
| PH (1) | PH12014502484A1 (es) |
| PL (1) | PL2849760T3 (es) |
| PT (1) | PT2849760T (es) |
| RS (1) | RS59914B1 (es) |
| SG (1) | SG11201407261XA (es) |
| SI (1) | SI2849760T1 (es) |
| TW (1) | TWI648288B (es) |
| WO (1) | WO2013170385A1 (es) |
| ZA (1) | ZA201408082B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008317566B2 (en) | 2007-10-26 | 2014-05-01 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| AU2013212758A1 (en) | 2012-01-27 | 2014-08-14 | Biomarin Technologies B.V. | RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy |
| IN2015DN01087A (es) | 2012-08-30 | 2015-06-26 | Replicor Inc | |
| CN113564168A (zh) | 2015-04-23 | 2021-10-29 | 美国杰龙生物医药公司 | 使用多价阳离子盐组合物制备多核苷酸的方法 |
| JP2019507579A (ja) | 2015-10-28 | 2019-03-22 | クリスパー セラピューティクス アーゲー | デュシェンヌ型筋ジストロフィーの処置のための材料および方法 |
| SG10202008046UA (en) | 2015-12-23 | 2020-09-29 | Univ Queensland Technology | Nucleic acid oligomers and uses therefor |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2022229350A2 (en) | 2021-04-30 | 2022-11-03 | Tirmed Pharma Ab | Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08506734A (ja) * | 1993-04-01 | 1996-07-23 | アイシス・ファーマシューティカルス・インコーポレーテッド | ｍＲＮＡキャップ活性に干渉しおよび翻訳を阻害するアンチセンスオリゴ類 |
| US20020166764A1 (en) * | 1997-08-12 | 2002-11-14 | University Of Southern California | Electrochemical sensor devices and methods for fast, reliable, and sensitive detection and quantitation of analytes |
| US20050020525A1 (en) * | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| WO2004024919A1 (en) * | 2002-09-13 | 2004-03-25 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
| CN1694959A (zh) * | 2002-09-13 | 2005-11-09 | 雷普利瑟公司 | 非序列互补的抗病毒寡核苷酸 |
| AU2005297376A1 (en) * | 2004-10-19 | 2006-04-27 | Replicor Inc. | Antiviral oligonucleotides |
| EP1942911A4 (en) | 2005-09-29 | 2009-08-19 | Replicor Inc | THERAPEUTIC MOLECULES AND USES THEREOF |
| CA2660052A1 (en) * | 2006-08-04 | 2008-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of jnk proteins |
| WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
| WO2009109665A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| US9107933B2 (en) | 2009-03-16 | 2015-08-18 | Isis Pharmaceuticals, Inc. | Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III |
| WO2010138806A2 (en) * | 2009-05-28 | 2010-12-02 | Curna, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| PT2605794T (pt) | 2010-08-20 | 2016-10-25 | Replicor Inc | Complexos de quelato de oligonucleótido |
-
2013
- 2013-05-16 AR ARP130101695A patent/AR091065A1/es not_active Application Discontinuation
- 2013-05-17 US US13/896,427 patent/US9616083B2/en active Active
- 2013-05-17 BR BR112014028568-3A patent/BR112014028568B1/pt active IP Right Grant
- 2013-05-17 IN IN8982DEN2014 patent/IN2014DN08982A/en unknown
- 2013-05-17 EA EA201401276A patent/EA034799B1/ru unknown
- 2013-05-17 KR KR1020147035251A patent/KR101975915B1/ko active IP Right Grant
- 2013-05-17 SG SG11201407261XA patent/SG11201407261XA/en unknown
- 2013-05-17 DK DK13791584.9T patent/DK2849760T3/da active
- 2013-05-17 JP JP2015511876A patent/JP6294308B2/ja active Active
- 2013-05-17 CN CN201380025475.XA patent/CN104379152B/zh active Active
- 2013-05-17 WO PCT/CA2013/050378 patent/WO2013170385A1/en active Application Filing
- 2013-05-17 MY MYPI2014003113A patent/MY168209A/en unknown
- 2013-05-17 AU AU2013262415A patent/AU2013262415B2/en active Active
- 2013-05-17 PT PT137915849T patent/PT2849760T/pt unknown
- 2013-05-17 EP EP13791584.9A patent/EP2849760B1/en active Active
- 2013-05-17 MX MX2014013885A patent/MX360626B/es active IP Right Grant
- 2013-05-17 SI SI201331646T patent/SI2849760T1/sl unknown
- 2013-05-17 ES ES13791584T patent/ES2767333T3/es active Active
- 2013-05-17 HU HUE13791584A patent/HUE047456T2/hu unknown
- 2013-05-17 LT LTEP13791584.9T patent/LT2849760T/lt unknown
- 2013-05-17 NZ NZ701931A patent/NZ701931A/en unknown
- 2013-05-17 CA CA2873526A patent/CA2873526C/en active Active
- 2013-05-17 RS RS20200065A patent/RS59914B1/sr unknown
- 2013-05-17 PL PL13791584T patent/PL2849760T3/pl unknown
- 2013-05-17 TW TW102117593A patent/TWI648288B/zh active
-
2014
- 2014-10-30 IL IL235402A patent/IL235402B/en unknown
- 2014-11-04 ZA ZA2014/08082A patent/ZA201408082B/en unknown
- 2014-11-06 PH PH12014502484A patent/PH12014502484A1/en unknown
- 2014-11-14 CR CR20140522A patent/CR20140522A/es unknown
- 2014-11-17 CU CU2014000132A patent/CU20140132A7/es unknown
- 2014-11-17 EC ECIEPI201427542A patent/ECSP14027542A/es unknown
- 2014-11-18 DO DO2014000263A patent/DOP2014000263A/es unknown
- 2014-11-18 CL CL2014003135A patent/CL2014003135A1/es unknown
- 2014-11-19 CO CO14254326A patent/CO7131388A2/es unknown
-
2015
- 2015-07-20 HK HK15106885.8A patent/HK1206259A1/xx unknown
-
2017
- 2017-11-02 JP JP2017212508A patent/JP2018058853A/ja active Pending
-
2020
- 2020-01-13 HR HRP20200045TT patent/HRP20200045T1/hr unknown
- 2020-01-21 CY CY20201100051T patent/CY1122856T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7131388A2 (es) | Métodos de quelatos de oligonucleótidos | |
| PH12016500486A1 (en) | Aza-pyridone compounds and uses thereof | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| MD4589C1 (ro) | Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C | |
| BR112015022674A2 (pt) | inibidores de bromodomínio | |
| EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| CY1124345T1 (el) | Συνθεσεις πολυπεπτιδιων-συμπλοκων χηλικων ενωσεων ολιγονουκλεοτιδιων και μεθοδοι | |
| BR112015016033A2 (pt) | composições e métodos para tratamento de infecções por bactérias | |
| CL2015003431A1 (es) | Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales | |
| TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
| PL2939665T3 (pl) | Kompozycja farmaceutyczna do leczenia zakażeń hiv | |
| BR112015006220A2 (pt) | agentes antibacterianos de tetrahidroquinolina tricíclica | |
| EA201591192A1 (ru) | Антибактериальные соединения | |
| MX2015014657A (es) | Nuevos agentes antibacterianos de fenicol. | |
| BR112014009217A2 (pt) | antibacterianos à base de fenicol | |
| CU20140133A7 (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
| CL2012001964A1 (es) | Uso de compuestos multiciclicos seleccionados de ingenoles, lanosta-8,24-dien-3-oles y sus mezclas para la produccion de composiciones farmaceuticas para la prevencion o tratamiento de infecciones de vih. |